The AdaptDx Pro and Theia will change the future of AMD care because they make it easier for eye care professionals to test more patients and diagnose disease at an earlier stage.
Subclinical AMD Detection
Research reveals that impaired dark adaptation is the earliest biomarker of AMD. Diagnosis at the subclinical level is the best chance to preserve vision.
Breakthrough Technology Meets High-Touch Patient Care
Measuring dark adaptation speed with the AdaptDx Pro® can be useful in diagnosing AMD at the subclinical stage and managing this progressive disease with the hope of preventing unnecessary vision loss.
The AdaptDx Pro is amazing for two primary reasons. One, the portability of it is phenomenal. The other piece that’s critical is that Theia, the onboard AI tech, provides the instructions for the test, so patients get consistent instructions every time.
Latest News & Upcoming EventsView More
Getting to know your practice and what drives you to take great care of your patients, especially when it comes to AMD, is crucial. Christine Akers, Practice Management Consultant at MacuLogix, gives 4 steps for standardization for a successful AMD Program.
It’s an exciting time to be in eye care with so many new tools available and in the development pipeline. The AdaptDx Pro is a dark adaptomter that measures dark adaptation speed. This can be used to identify AMD with 90% sensitivity.
Your technician can operate the AdaptDx Pro in one language while selecting a different one for the patient to experience. Tailoring patient instructions to their native language can improve communication and trust.